---
title: 'Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing
  endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): a multicentre,
  double-blind, randomised controlled trial'
date: '2025-02-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39955119/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250216171018&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: In the ESCAPE-NA1 trial, treatment with nerinetide, an eicosapeptide
  that interferes with post-synaptic density protein 95, was associated with improved
  functional outcome among patients with acute ischaemic stroke due to large vessel
  occlusion undergoing endovascular thrombectomy without co-treatment with an intravenous
  thrombolytic agent. There was no benefit when intravenous thrombolytic agent co-treatment
  was used. We sought to confirm the clinical benefit of nerinetide in ...'
disable_comments: true
---
BACKGROUND: In the ESCAPE-NA1 trial, treatment with nerinetide, an eicosapeptide that interferes with post-synaptic density protein 95, was associated with improved functional outcome among patients with acute ischaemic stroke due to large vessel occlusion undergoing endovascular thrombectomy without co-treatment with an intravenous thrombolytic agent. There was no benefit when intravenous thrombolytic agent co-treatment was used. We sought to confirm the clinical benefit of nerinetide in ...